<DOC>
	<DOCNO>NCT02034513</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial compare safety efficacy insulin degludec ( IDeg ) insulin glargine ( IGlar ) , insulin aspart ( IAsp ) mealtime insulin subject type 1 diabetes .</brief_summary>
	<brief_title>A Trial Comparing Safety Efficacy Insulin Degludec Insulin Glargine , Both With Insulin Aspart Mealtime Insulin Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Subjects fulfil least one criterion : ) Experienced least one severe hypo episode within last year ( accord ADA ( American Diabetes Association ) definition , April 2013 ) b ) Moderate chronic renal failure , define glomerular filtration rate 30 59 mL/min/1.73 m^2 per CKDEpi ( chronic kidney disease epidemiology collaboration ) c ) Hypoglycaemic symptom unawareness ) Diabetes mellitus duration 15 year e ) Recent episode hypoglycaemia ( define symptom hypoglycaemia and/or episode low glucose measurement ( equal 70 mg/dL [ equal 3.9 mmol/L ] ) ) within last 12 week prior Visit 1 ( screen ) Male female , age least 18 year time signing informed consent Type 1 diabetes mellitus ( diagnose clinically ) least 52 week prior Visit 1 Current treatment basalbolus regimen consist neutral protamine Hagedorn ( NPH ) insulin OD ( daily ) / BID ( twice daily ) insulin detemir ( IDet ) OD / BID plus 24 daily injection rapid act meal time insulin CSII ( rapid act insulin ) least 26 week prior Visit 1 HbA1c ( glycosylated haemoglobin ) equal 10 % central laboratory analysis BMI ( body mass index ) equal 45 kg/m^2 Treatment IGlar IDeg within last 26 week prior Visit 1 ( short term use [ le equal 2 week ] allow , within 4 week prior screen ) Use antidiabetic agent state inclusion criterion within last 26 week prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>